Location: Belgium, East Flanders, Ghent
Employees: 1-10
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A
Portfolio 17
| Date | Name | Website | Total Raised | Location |
| 20.03.2024 | rheumafinder.ai | - | - | |
| 09.12.2023 | myneotx.com | - | - | |
| 07.02.2023 | Rarity Bio... | raritybioscience.com | $3.13M | Sweden, Up... |
| 31.01.2023 | C-mo Medic... | c-mo.solutions | $9.33M | - |
| 24.05.2022 | Alithea Ge... | alitheagenomics.com | $4.22M | United Sta... |
| 07.06.2021 | Rheavita | rheavita.com | $3.05M | - |
| 09.02.2021 | Grapheal | grapheal.com | $2.3M | France, Au... |
| - | Cergentis | cergentis.com | - | Argentina,... |
| - | Trince Bio | trincebio.com | $4.53M | Belgium, E... |
| - | Epify BV | epify.nl | $564.63K | Netherland... |
Show more
Persons 9
| Date | First Name | Last Name | Title | Location | |||
| - | Cedric | Bogaert | - | linkedin.c... | - | - | - |
| - | Jan | Van den Be... | - | linkedin.c... | - | j*n@noval.... | - |
| - | Kathleen | Van den Be... | - | linkedin.c... | - | - | - |
| - | Wim | Van Crieki... | - | linkedin.c... | - | w*m@noval.... | - |
| - | Jaroslav | Belotserko... | - | linkedin.c... | - | - | - |
| - | Kjell | Mortier | - | linkedin.c... | - | - | - |
| - | Liesbeth | Ceelen | - | - | - | - | |
| - | Michael | Hengartner | - | - | - | - | |
| - | Bart | Rossel | - | - | - | - |
News 41
| Date | Title | Description |
| 08.08.2024 | Anacura acquires OHMX.bio, a Novalis fund I portfolio company, and extends its service with multi-omics for drug discovery and diagnostics | July 4th, 2024. Ghent, Belgium Anacura acquires OHMX.bio, a Novalis fund I portfolio company, and extends its service with multi-omics for drug discovery and diagnostics |
| 08.08.2024 | Novalis II portfolio company Trince awarded winner of Nature Spinoff Prize 2024 | July 11th 2024, Ghent (BE). Novalis II portfolio company Trince is awarded the Spinoff Prize from the prestigious Nature Magazine |
| 08.08.2024 | Rarity Bioscience announces the successful closure of a €6.5 million funding round | June, 18th 2024, Uppsala, Sweden. Rarity Bioscience, a pioneering molecular biotech company, is pleased to announce the successful closure of a €6.5 million funding round.... |
| 14.03.2024 | Alithea Genomics Closes CHF 2.8 Million in Seed Financing Extension Led by Novalis Biotech | Alithea Genomics, an emerging leader in the field of large-scale RNA sequencing and transcriptomics, announced today the closing of a CHF 2.8 million ($3.2 million)... |
| 02.03.2024 | Altavo concludes Series A for the development of its Artificial Voice | Altavo, a startup in AI-based voice rehabilitation founded in 2021, successfully closed its Series A financing round on February 1, 2024. |
| 02.03.2024 | RheumaFinder Announces Investment to revolutionize care for patients with rheumatic disease | Ghent, Belgium, February 2024 – RheumaFinder is excited to announce an investment from Belgium's Novalis Biotech Acceleration Fund. This investment, executed as a seed-participation in... |
| 27.11.2023 | myNEO evolves into myNEO Therapeutics to reflect its new strategy to develop off-the-shelf cancer vaccine immunotherapeutics. | |
| 03.03.2023 | C-mo Medical Solutions extends seed investment round to €4.8 million to transform cough monitoring | |
| 03.03.2023 | Novalis Biotech invests in Rarity Bioscience’s ultra sensitive genomics technology | |
| 04.11.2022 | Enzyre closes Series A financing round of EUR 12M to advance pioneering diagnostic technology platform for hemophilia patients |
Show more
Mentions in press and media 16
| Date | Title | Description |
| 17.03.2024 | Alithea Genomics Revolutionizes RNA Sequencing with CHF 2.8 Million Seed Financing Extension | Alithea Genomics, a game-changer in RNA sequencing, secures CHF 2.8 million in seed financing extension led by Novalis Biotech. Their innovative BRB-seq and DRUG-seq technologies streamline RNA sample preparation, slashing costs and time. B... |
| 14.03.2024 | Alithea Genomics Closes CHF 2.8 Million in Seed Financing Extension Led by Novalis Biotech | Alithea Genomics, an emerging leader in the field of large-scale RNA sequencing and transcriptomics, announced today the closing of a CHF 2.8 million ($3.2 million)... |
| 14.03.2024 | Alithea Genomics secures CHF 2.8 million in Seed financing extension led by Novalis Biotech | Alithea Genomics secures CHF 2.8 million in Seed financing extension led by Novalis Biotech 14.03.2024 08:01, Rita Longobardi linkedIn facebook twitter instagram youtube --> The funding will support the commercialization and manufacturin... |
| 14.03.2024 | Alithea Genomics secures CHF 2.8 million in Seed financing extension led by Novalis Biotech | Alithea commercializes multiplexed library preparation solutions for RNA sequencing, most notably BRB-seq and DRUG-seq. These technologies prepare hundreds of RNA samples for sequencing in a single tube and, in the case of DRUG-seq, without... |
| 14.03.2024 | Alithea Genomics eyes the US market after closing seed round | Based in Lausanne, Alithea Genomics is an emerging company in the field of large-scale RNA sequencing and transcriptomics. The company commercializes massively multiplexed library preparation solutions for RNA sequencing, with two products... |
| 08.09.2022 | France-based Carroucell raises EUR 1.5 million in Series A | Grenoble, a France-based microcarrier supplier for cell culture in the bioreactor, Carroucell raised EUR 1.5 million. The Series A funding took place on September 7, 2022. Novalis Biotech Acceleration fund led the financing for the company.... |
| 10.06.2022 | Alithea Genomics Raises CHF 1 Million in Seed Financing Round Led by Novalis Biotech | |
| 24.05.2022 | Alithea Genomics completes seed round | |
| 01.07.2021 | Novalis Biotech closes second fund on €25M | Early-stage investor Novalis Biotech has closed its second Biotech Acceleration Fund on €25 million. The vehicle will be used to back startups and scale-up companies reshaping healthcare with technologies such as bioinformatics and genomics... |
| 02.06.2021 | RheaVita : Closes EUR 2.5 million Series A Financing Co-Led by Novalis Biotech Acceleration and PMV | RheaVita, a company pioneering continuous freeze-drying technology for biopharmaceutical products, announced today that the company has closed a EUR 2.5 million Series A Financing. The round was co-led by Novalis Biotech Acceleration and Pa... |
Show more